This section is provided for qualified healthcare practitioners as professional education. It summarises selected ingredient-level, pathway-level and traditional-use research relating to Magnolia officinalis, honokiol, Rhodiola rosea, Qi regulation, dampness, cold-phlegm and stress-response pathways. It does not represent additional ARTG indications for Magnol One.
Magnol One is relevant to practitioners interested in traditional Qi regulation, dampness and cold-phlegm patterns, Magnolia officinalis research, honokiol pathways, Rhodiola rosea research, adaptogen-style support and stress-response pathway education.
Magnolia officinalis contains honokiol and related lignans. Honokiol and magnolol have been discussed in professional literature in relation to neuropharmacological pathways, GABA-related signalling, inflammatory pathways, oxidative stress, cellular signalling and stress-related research. This supports practitioner education around Magnolia officinalis and honokiol, but should not be interpreted as a claim that Magnol One treats anxiety, depression, burnout, neurological disease or mental health conditions.
Recent review literature has also discussed honokiol in relation to anti-inflammatory, antibacterial, photoprotective and selected oncology-related pathway research. This information is provided as scientific background only and does not represent a cancer, infection or dermatological indication for Magnol One.
Rhodiola rosea is widely discussed in professional literature in relation to adaptogen-style research, stress-response pathways, fatigue research, oxidative stress, physical endurance and cognitive performance pathways. A recent systematic review and meta-analysis examined Rhodiola rosea supplementation in endurance performance and related biomarkers, including oxidative stress, inflammation and muscle damage markers. This supports practitioner education around Rhodiola rosea research, but should not be interpreted as a claim that Magnol One treats chronic fatigue, post-viral fatigue, burnout, disease-related fatigue or cognitive impairment.
Recent systematic review literature has also examined adaptogenic effects of Rhodiola rosea in relation to stress and psychometric outcomes. This supports professional education around adaptogen-style research, while remaining separate from the ARTG indications for Magnol One.
The combination of Magnolia officinalis and Rhodiola rosea supports practitioner education around Qi regulation, dampness and cold-phlegm traditional contexts, together with ingredient-level research on honokiol, stress-response pathways and adaptogen-style botanical research.
This information is provided for practitioner education only and does not represent additional ARTG indications for Magnol One.
References available to registered practitioners on request.
